Assessing the impact of chemotherapy-induced nausea and vomiting on patients' daily lives: A modified version of the Functional Living Index-Emesis (FLIE) with 5-day recall

A. R. Martin, J. D. Pearson, B. Cai, M. Elmer, K. Horgan, C. Lindley

Research output: Contribution to journalArticle

Abstract

Background: The Functional Living Index - Emesis (FLIE), a patient-reported outcome measure, was originally developed to assess the impact of chemotherapy-induced nausea and vomiting (CINV) on patients' daily lives over the 3 days following chemotherapy. More recent studies of CINV include assessments covering the 5 days following chemotherapy in an effort to capture information during both the acute (within 24 h) and delayed (up to 5-7 days) phases of CINV. Goals: To assess the measurement characteristics of a modified version of the FLIE with 5-day recall. Instrument reliability, validity, and missing data were assessed. Patients and methods: Data were collected from 183 patients receiving cisplatin ≥ 70 mg/m2 as part of a phase IIb antiemetic trial of an NK-1 receptor antagonist (MK-0869). Patients recorded the number of vomiting episodes and nausea ratings in a 5-day daily diary. Results: The 5-day FLIE had: (1) excellent internal consistency within FLIE Nausea and Vomiting domains (Cronbach's alpha 0.77-0.78), (2) acceptable construct validity shown by FLIE item-total correlations stronger within domains (r=0.74-0.97) than across domains (r=0.52-0.76), and (3) acceptable convergent validity as shown by moderate to strong correlations between FLIE domain scores and independent endpoints of emetic episodes, nausea ratings, and use of rescue medications. The extent of missing data was within acceptable limits with less than 2% of patients missing data. Conclusion: The 5-day FLIE had adequate measurement characteristics for studying the impact of CINV on patients' daily lives during the period covering both the acute and delayed phases.

Original languageEnglish (US)
Pages (from-to)522-527
Number of pages6
JournalSupportive Care in Cancer
Volume11
Issue number8
DOIs
StatePublished - Aug 1 2003
Externally publishedYes

Fingerprint

Nausea
Vomiting
Drug Therapy
aprepitant
Emetics
Neurokinin-1 Receptors
Antiemetics
Reproducibility of Results
Cisplatin

Keywords

  • Chemotherapy-induced nausea and vomiting
  • FLIE
  • Health-related quality of life
  • Patient-reported outcomes

ASJC Scopus subject areas

  • Oncology
  • Nursing(all)

Cite this

Assessing the impact of chemotherapy-induced nausea and vomiting on patients' daily lives : A modified version of the Functional Living Index-Emesis (FLIE) with 5-day recall. / Martin, A. R.; Pearson, J. D.; Cai, B.; Elmer, M.; Horgan, K.; Lindley, C.

In: Supportive Care in Cancer, Vol. 11, No. 8, 01.08.2003, p. 522-527.

Research output: Contribution to journalArticle

@article{986703ff90d34969938fc4aacbb2edf0,
title = "Assessing the impact of chemotherapy-induced nausea and vomiting on patients' daily lives: A modified version of the Functional Living Index-Emesis (FLIE) with 5-day recall",
abstract = "Background: The Functional Living Index - Emesis (FLIE), a patient-reported outcome measure, was originally developed to assess the impact of chemotherapy-induced nausea and vomiting (CINV) on patients' daily lives over the 3 days following chemotherapy. More recent studies of CINV include assessments covering the 5 days following chemotherapy in an effort to capture information during both the acute (within 24 h) and delayed (up to 5-7 days) phases of CINV. Goals: To assess the measurement characteristics of a modified version of the FLIE with 5-day recall. Instrument reliability, validity, and missing data were assessed. Patients and methods: Data were collected from 183 patients receiving cisplatin ≥ 70 mg/m2 as part of a phase IIb antiemetic trial of an NK-1 receptor antagonist (MK-0869). Patients recorded the number of vomiting episodes and nausea ratings in a 5-day daily diary. Results: The 5-day FLIE had: (1) excellent internal consistency within FLIE Nausea and Vomiting domains (Cronbach's alpha 0.77-0.78), (2) acceptable construct validity shown by FLIE item-total correlations stronger within domains (r=0.74-0.97) than across domains (r=0.52-0.76), and (3) acceptable convergent validity as shown by moderate to strong correlations between FLIE domain scores and independent endpoints of emetic episodes, nausea ratings, and use of rescue medications. The extent of missing data was within acceptable limits with less than 2{\%} of patients missing data. Conclusion: The 5-day FLIE had adequate measurement characteristics for studying the impact of CINV on patients' daily lives during the period covering both the acute and delayed phases.",
keywords = "Chemotherapy-induced nausea and vomiting, FLIE, Health-related quality of life, Patient-reported outcomes",
author = "Martin, {A. R.} and Pearson, {J. D.} and B. Cai and M. Elmer and K. Horgan and C. Lindley",
year = "2003",
month = "8",
day = "1",
doi = "10.1007/s00520-003-0482-4",
language = "English (US)",
volume = "11",
pages = "522--527",
journal = "Supportive Care in Cancer",
issn = "0941-4355",
publisher = "Springer Verlag",
number = "8",

}

TY - JOUR

T1 - Assessing the impact of chemotherapy-induced nausea and vomiting on patients' daily lives

T2 - A modified version of the Functional Living Index-Emesis (FLIE) with 5-day recall

AU - Martin, A. R.

AU - Pearson, J. D.

AU - Cai, B.

AU - Elmer, M.

AU - Horgan, K.

AU - Lindley, C.

PY - 2003/8/1

Y1 - 2003/8/1

N2 - Background: The Functional Living Index - Emesis (FLIE), a patient-reported outcome measure, was originally developed to assess the impact of chemotherapy-induced nausea and vomiting (CINV) on patients' daily lives over the 3 days following chemotherapy. More recent studies of CINV include assessments covering the 5 days following chemotherapy in an effort to capture information during both the acute (within 24 h) and delayed (up to 5-7 days) phases of CINV. Goals: To assess the measurement characteristics of a modified version of the FLIE with 5-day recall. Instrument reliability, validity, and missing data were assessed. Patients and methods: Data were collected from 183 patients receiving cisplatin ≥ 70 mg/m2 as part of a phase IIb antiemetic trial of an NK-1 receptor antagonist (MK-0869). Patients recorded the number of vomiting episodes and nausea ratings in a 5-day daily diary. Results: The 5-day FLIE had: (1) excellent internal consistency within FLIE Nausea and Vomiting domains (Cronbach's alpha 0.77-0.78), (2) acceptable construct validity shown by FLIE item-total correlations stronger within domains (r=0.74-0.97) than across domains (r=0.52-0.76), and (3) acceptable convergent validity as shown by moderate to strong correlations between FLIE domain scores and independent endpoints of emetic episodes, nausea ratings, and use of rescue medications. The extent of missing data was within acceptable limits with less than 2% of patients missing data. Conclusion: The 5-day FLIE had adequate measurement characteristics for studying the impact of CINV on patients' daily lives during the period covering both the acute and delayed phases.

AB - Background: The Functional Living Index - Emesis (FLIE), a patient-reported outcome measure, was originally developed to assess the impact of chemotherapy-induced nausea and vomiting (CINV) on patients' daily lives over the 3 days following chemotherapy. More recent studies of CINV include assessments covering the 5 days following chemotherapy in an effort to capture information during both the acute (within 24 h) and delayed (up to 5-7 days) phases of CINV. Goals: To assess the measurement characteristics of a modified version of the FLIE with 5-day recall. Instrument reliability, validity, and missing data were assessed. Patients and methods: Data were collected from 183 patients receiving cisplatin ≥ 70 mg/m2 as part of a phase IIb antiemetic trial of an NK-1 receptor antagonist (MK-0869). Patients recorded the number of vomiting episodes and nausea ratings in a 5-day daily diary. Results: The 5-day FLIE had: (1) excellent internal consistency within FLIE Nausea and Vomiting domains (Cronbach's alpha 0.77-0.78), (2) acceptable construct validity shown by FLIE item-total correlations stronger within domains (r=0.74-0.97) than across domains (r=0.52-0.76), and (3) acceptable convergent validity as shown by moderate to strong correlations between FLIE domain scores and independent endpoints of emetic episodes, nausea ratings, and use of rescue medications. The extent of missing data was within acceptable limits with less than 2% of patients missing data. Conclusion: The 5-day FLIE had adequate measurement characteristics for studying the impact of CINV on patients' daily lives during the period covering both the acute and delayed phases.

KW - Chemotherapy-induced nausea and vomiting

KW - FLIE

KW - Health-related quality of life

KW - Patient-reported outcomes

UR - http://www.scopus.com/inward/record.url?scp=0043236088&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0043236088&partnerID=8YFLogxK

U2 - 10.1007/s00520-003-0482-4

DO - 10.1007/s00520-003-0482-4

M3 - Article

C2 - 12827483

AN - SCOPUS:0043236088

VL - 11

SP - 522

EP - 527

JO - Supportive Care in Cancer

JF - Supportive Care in Cancer

SN - 0941-4355

IS - 8

ER -